Skip to main content

Advertisement

ADVERTISEMENT

videos

Gail Roboz, MD, Weill Cornell Medicine
Videos
02/23/2023
Gail J. Roboz, MD, provides some key points to consider when handling challenging management issues in AML at the 2022 Lymphoma, Leukemia & Myeloma Congress in New York.
Gail J. Roboz, MD, provides some key points to consider when handling challenging management issues in AML at the 2022 Lymphoma, Leukemia & Myeloma Congress in New York.
Gail J. Roboz, MD, provides some...
02/23/2023
Oncology
Dan Vogl, MD, University of Pennsylvania
Videos
02/23/2023
Dan Vogl, MD discusses options for bispecific T-Cell engagers when treating patients with multiple myeloma.
Dan Vogl, MD discusses options for bispecific T-Cell engagers when treating patients with multiple myeloma.
Dan Vogl, MD discusses options...
02/23/2023
Oncology
Faith Davies, MD
Videos
02/16/2023
Faith E. Davies, MD, provides an update on treatment options for patients with multiple myeloma in early relapse at the 2022 Lymphoma, Leukemia & Myeloma Congress in New York.
Faith E. Davies, MD, provides an update on treatment options for patients with multiple myeloma in early relapse at the 2022 Lymphoma, Leukemia & Myeloma Congress in New York.
Faith E. Davies, MD, provides an...
02/16/2023
Oncology
Pinkal Desai, MD
Videos
02/15/2023
Pinkal Desai, MD, provides the latest updates on clonal hematopoiesis, highlighting what doctors should know about these aging-associated mutations.
Pinkal Desai, MD, provides the latest updates on clonal hematopoiesis, highlighting what doctors should know about these aging-associated mutations.
Pinkal Desai, MD, provides the...
02/15/2023
Oncology
Shaji Kumar, MD
Videos
01/26/2023
Shaji Kumar, MD, provides insight into approaches for treating frail and transplant-ineligible patients with multiple myeloma.
Shaji Kumar, MD, provides insight into approaches for treating frail and transplant-ineligible patients with multiple myeloma.
Shaji Kumar, MD, provides...
01/26/2023
Oncology
Javid Moslehi, MD
Videos
12/06/2022
Javid Moslehi, MD, discusses the cardiovascular risks associated with utilization of BTK inhibitors for patients with CLL and outlines best practices for managing these adverse events.
Javid Moslehi, MD, discusses the cardiovascular risks associated with utilization of BTK inhibitors for patients with CLL and outlines best practices for managing these adverse events.
Javid Moslehi, MD, discusses the...
12/06/2022
Oncology
Jia Ruan, MD
Videos
12/01/2022
Jia Ruan, MD, highlights recent advancements in the treatment of patients with T-Cell non-Hodgkin lymphoma, presenting updated information on novel agents and ongoing clinical trials in this space.
Jia Ruan, MD, highlights recent advancements in the treatment of patients with T-Cell non-Hodgkin lymphoma, presenting updated information on novel agents and ongoing clinical trials in this space.
Jia Ruan, MD, highlights recent...
12/01/2022
Oncology
Julie Vose, MD
Videos
11/22/2022
Julie Vose, MD, provides insight into the latest approaches to initial therapy for patients with aggressive diffuse large B-cell lymphoma at the 2022 Lymphoma, Leukemia & Myeloma Congress in New York.
Julie Vose, MD, provides insight into the latest approaches to initial therapy for patients with aggressive diffuse large B-cell lymphoma at the 2022 Lymphoma, Leukemia & Myeloma Congress in New York.
Julie Vose, MD, provides insight...
11/22/2022
Oncology
Othman Al-Sawaf, MD
Videos
11/15/2022
Othman Al-Sawaf, MD, provides insight into the best use of minimal residual disease in the management of patients with CLL, which he presented at the 2022 Lymphoma, Leukemia & Myeloma Congress.
Othman Al-Sawaf, MD, provides insight into the best use of minimal residual disease in the management of patients with CLL, which he presented at the 2022 Lymphoma, Leukemia & Myeloma Congress.
Othman Al-Sawaf, MD, provides...
11/15/2022
Oncology
Asher Chanan-Khan, MD
Videos
11/14/2022
Asher Chanan-Khan, MD, argues in favor of BTK inhibitors over BCL-2 inhibitors for the frontline treatment of patients with CLL in a debate at the 2022 Lymphoma, Leukemia & Myeloma Congress.
Asher Chanan-Khan, MD, argues in favor of BTK inhibitors over BCL-2 inhibitors for the frontline treatment of patients with CLL in a debate at the 2022 Lymphoma, Leukemia & Myeloma Congress.
Asher Chanan-Khan, MD, argues in...
11/14/2022
Oncology

Advertisement